| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)
ZNTL Technical Analysis
5
| As on 2nd Dec 2024 ZNTL SHARE Price closed @ 3.66 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 17.69 & Strong Sell for SHORT-TERM with Stoploss of 26.89 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ZNTLSHARE Price
| Open | 3.71 | Change | Price | % |
| High | 3.90 | 1 Day | 0.05 | 1.39 |
| Low | 3.61 | 1 Week | 0.67 | 22.41 |
| Close | 3.66 | 1 Month | 0.64 | 21.19 |
| Volume | 1068114 | 1 Year | -23.96 | -86.75 |
| 52 Week High 29.66 | 52 Week Low 2.70 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| OPTT | 0.70 | 40.00% |
| SMCI | 42.00 | 28.68% |
| NVDA | 138.63 | 0.27% |
| INTC | 23.93 | -0.50% |
| MARA | 25.63 | -6.53% |
| LMDX | 0.02 | 0.00% |
| PLUG | 2.30 | 2.68% |
| SGBX | 0.68 | 41.67% |
| TSLA | 357.09 | 3.46% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ZNTL Daily Charts |
ZNTL Intraday Charts |
Whats New @ Bazaartrend |
ZNTL Free Analysis |
|
|
ZNTL Important Levels Intraday
| RESISTANCE | 4.22 |
| RESISTANCE | 4.04 |
| RESISTANCE | 3.93 |
| RESISTANCE | 3.82 |
| SUPPORT | 3.50 |
| SUPPORT | 3.39 |
| SUPPORT | 3.28 |
| SUPPORT | 3.10 |
ZNTL Forecast December 2024
| 4th UP Forecast | 14.26 |
| 3rd UP Forecast | 10.86 |
| 2nd UP Forecast | 8.76 |
| 1st UP Forecast | 6.66 |
| 1st DOWN Forecast | 0.66 |
| 2nd DOWN Forecast | -1.44 |
| 3rd DOWN Forecast | -3.54 |
| 4th DOWN Forecast | -6.94 |
ZNTL Weekly Forecast
| 4th UP Forecast | 10.04 |
| 3rd UP Forecast | 7.99 |
| 2nd UP Forecast | 6.73 |
| 1st UP Forecast | 5.46 |
| 1st DOWN Forecast | 1.86 |
| 2nd DOWN Forecast | 0.59 |
| 3rd DOWN Forecast | -0.67 |
| 4th DOWN Forecast | -2.72 |
ZNTL Forecast2024
| 4th UP Forecast | 57.37 |
| 3rd UP Forecast | 40.14 |
| 2nd UP Forecast | 29.5 |
| 1st UP Forecast | 18.85 |
| 1st DOWN Forecast | -11.53 |
| 2nd DOWN Forecast | -22.18 |
| 3rd DOWN Forecast | -32.82 |
| 4th DOWN Forecast | -50.05 |
Zentalis Pharmaceuticals Inc ( NASDAQ USA Symbol : ZNTL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ZNTL Business Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. Address: 530 Seventh Avenue, New York, NY, United States, 10018
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service